Marex Group plc [MRX] vs Morgan Stanley [MS] Detailed Stock Comparison

Marex Group plc

NASDAQ
Loading...

Morgan Stanley

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Marex Group plc wins in 5 metrics, Morgan Stanley wins in 13 metrics, with 0 ties. Morgan Stanley appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Marex Group plc Morgan Stanley Better
P/E Ratio (TTM) 13.68 17.31 Marex Group plc
Price-to-Book Ratio 3.25 2.97 Morgan Stanley
Debt-to-Equity Ratio 988.35 455.75 Morgan Stanley
PEG Ratio 9.95 0.53 Morgan Stanley
EV/EBITDA 3.75 N/A N/A
Profit Margin (TTM) 10.71% 24.75% Morgan Stanley
Operating Margin (TTM) 19.46% 40.62% Morgan Stanley
EBITDA Margin (TTM) 19.46% 40.62% Morgan Stanley
Return on Equity 27.49% 14.42% Marex Group plc
Return on Assets (TTM) 1.04% 1.14% Morgan Stanley
Free Cash Flow (TTM) $647.70M $-20.79B Marex Group plc
Dividend Yield 1.92% 2.15% Morgan Stanley
1-Year Return 22.66% 62.46% Morgan Stanley
Price-to-Sales Ratio (TTM) 1.32 4.15 Marex Group plc
Enterprise Value $4.51B $225.65B Morgan Stanley
EV/Revenue Ratio 1.57 3.08 Marex Group plc
Gross Profit Margin (TTM) 52.49% N/A N/A
Revenue per Share (TTM) $40 $47 Morgan Stanley
Earnings per Share (Diluted) $3.86 $11.04 Morgan Stanley
Beta (Stock Volatility) N/A 1.18 N/A
Short % of Float 4.32% 0.00% Morgan Stanley

Marex Group plc vs Morgan Stanley Stock Performance Analysis

Loading Price Chart...

MRX
MS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Marex Group plc5.69%0.67%3.14%30.07%45.68%42.07%
Morgan Stanley-2.25%4.23%11.77%26.63%20.96%15.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Marex Group plc22.66%178.63%178.63%178.63%178.63%178.63%
Morgan Stanley62.46%146.59%121.37%683.72%799.65%243.29%

Performance & Financial Health Analysis: Marex Group plc vs Morgan Stanley

MetricMRXMS
Market Information
Market Cap i$3.80B$299.55B
Market Cap CategoryMid capMega cap
10 Day Avg. Volume i1,245,1506,501,123
90 Day Avg. Volume i1,289,1636,965,138
Last Close$53.90$210.14
52 Week Range$27.91 - $58.62$127.13 - $217.03
% from 52W High-8.05%-3.17%
All-Time High$58.61 (May 14, 2026)$217.03 (Jun 02, 2026)
% from All-Time High-8.04%-3.17%
Growth Metrics
Quarterly Revenue Growth-0.51%0.16%
Quarterly Earnings Growth0.50%0.29%
Financial Health
Profit Margin (TTM) i0.11%0.25%
Operating Margin (TTM) i0.19%0.41%
Return on Equity (TTM) i0.27%0.14%
Debt to Equity (MRQ) i988.35455.75
Cash & Liquidity
Book Value per Share (MRQ)$16.26$64.37
Cash per Share (MRQ)$163.99$379.99
Operating Cash Flow (TTM) i$667.50M$-95,740,000,000
Levered Free Cash Flow (TTM) i$293.90M$16.25B
Dividends
Last 12-Month Dividend Yield i1.92%2.15%
Last 12-Month Dividend i$0.74$3.93

Valuation & Enterprise Metrics Analysis: Marex Group plc vs Morgan Stanley

MetricMRX (Apr 26, 2026)MS (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i13.6817.31
Forward P/E i9.9515.16
PEG Ratio i9.950.53
Price to Sales (TTM) i1.324.15
Price to Book (MRQ) i3.252.97
Market Capitalization
Market Capitalization i$3.80B$299.55B
Enterprise Value i$4.51B$225.65B
Enterprise Value Metrics
Enterprise to Revenue i1.573.08
Enterprise to EBITDA i3.75N/A
Risk & Other Metrics
Beta iN/A1.18
Book Value per Share (MRQ) i$16.26$64.37

Financial Statements Comparison: Marex Group plc vs Morgan Stanley

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMRX (2025)MS (2025)
Revenue/Sales i3.63B65.97B
Cost of Goods Sold i1.92BN/A
COGS % of Revenue i53.0%0.0%
Gross Profit i1.71BN/A
Gross Margin i47.0%0.0%
Research & Development iN/AN/A
Operating Income (EBIT) i1.17BN/A
Operating Margin i32.3%0.0%
EBITDA i1.20BN/A
EBITDA Margin i33.2%0.0%
Pre-Tax Income i411.60M21.95B
Pre-Tax Income % of Revenue i11.3%33.3%
Income Tax i103.70M4.93B
Income Tax % of Revenue i2.9%7.5%
Net Income (Profit) i307.70M17.03B
Profit Margin i8.5%25.8%

Balance Sheet & Liquidity Metrics

MetricMRX (2025)MS (2025)
Cash & Equivalents i2.88B81.31B
Total Current Assets i33.70BN/A
Total Current Assets % of Revenue i928.3%0.0%
Total Current Liabilities i30.96BN/A
Total Current Liabilities % of Revenue i853.0%0.0%
Long-Term Debt i2.41B349.39B
Long-Term Debt % of Revenue i66.5%529.7%
Total Shareholders Equity i1.26B112.65B
Retained Earnings i982.00M115.09B
Retained Earnings % of Revenue i27.1%174.5%
Property, Plant & Equipment i020.00M

Cash Flow Statement Comparison

MetricMRX (2025)MS (2025)
Operating Cash Flow i-1.92B-95.74B
Operating Cash Flow % of Revenue i-52.9%-145.1%
Capital Expenditures i-13.10M-2.90B
Free Cash Flow i647.70M-20.79B
FCF Margin i17.8%-31.5%
Debt Repayment i-24.30M-99.39B
Common Stock Repurchase i-44.10M-5.84B

Short Interest & Institutional Ownership Analysis

MetricMRXMS
Shares Short i2.89M13,702
Short Ratio i2.090.00
Short % of Float i4.32%0.00%
Shares Outstanding i71.74M1.58B
Float Shares i50.51M1.20B
% Held by Insiders i15.77%24.27%
% Held by Institutions i72.68%63.01%
% Held by Public i11.55%12.72%

Dividend Analysis & Yield Comparison: Marex Group plc vs Morgan Stanley

MetricMRXMS
Last 12-Month Dividend i$0.74$3.93
Last 12-Month Dividend Yield i1.92%2.15%
3-Year Avg Annual Dividend i$0.34$3.63
3-Year Avg Dividend Yield i0.44%0.83%
3-Year Total Dividends i$1.02$10.90
Ex-Dividend DateMar 16, 2026Jan 30, 2026